Carol Aghajanian1, Barbara Goff2, Lawrence R Nycum3, Yan V Wang4, Amreen Husain4, Stephanie V Blank5. 1. Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA. Electronic address: aghajanc@mskcc.org. 2. University of Washington School of Medicine, Seattle, WA, USA. 3. Novant Health Forsyth Cancer Center, Winston-Salem, NC, USA. 4. Genentech, Inc., South San Francisco, CA, USA. 5. NYU School of Medicine, New York, NY, USA.
Abstract
OBJECTIVE: OCEANS is a randomized, placebo (PL)-controlled, phase 3 trial evaluating the efficacy and safety of bevacizumab combined with gemcitabine+carboplatin (GC) for patients with platinum-sensitive recurrent ovarian cancer (ROC). The study met its primary endpoint, demonstrating improved progression-free survival with GC+bevacizumab compared with GC+PL. Herein, we describe results of final overall survival (OS) and updated safety. METHODS:Patients with recurrent platinum-sensitive ROC (recurring ≥6months after first-line platinum-based therapy) and measurable disease at baseline were randomized to receive GC+bevacizumab or GC+PL for 6-10cycles; PL or bevacizumab was then continued until disease progression. In this updated analysis, a Cox proportional hazards model was used to compare OS between the 2 treatment arms. RESULTS: At the data cutoff date (July 19, 2013), 353 patients (72.9%) had died. Median follow-up for OS was 58.2months in the experimental arm and 56.4months in the control arm. Consistent with interim analyses, median OS was comparable between arms (GC+bevacizumab: 33.6months; GC+PL: 32.9months; hazard ratio=0.95; log-rank p=0.65), and was consistent across all examined patient subgroups. The frequency and severity of adverse events were consistent with previous analyses; no new safety concerns were identified. CONCLUSIONS: Results from final OS analysis of the phase 3 OCEANS study showed no significant difference in OS for patients treated with GC+bevacizumab compared with GC+PL.
RCT Entities:
OBJECTIVE: OCEANS is a randomized, placebo (PL)-controlled, phase 3 trial evaluating the efficacy and safety of bevacizumab combined with gemcitabine+carboplatin (GC) for patients with platinum-sensitive recurrent ovarian cancer (ROC). The study met its primary endpoint, demonstrating improved progression-free survival with GC+bevacizumab compared with GC+PL. Herein, we describe results of final overall survival (OS) and updated safety. METHODS:Patients with recurrent platinum-sensitive ROC (recurring ≥6months after first-line platinum-based therapy) and measurable disease at baseline were randomized to receive GC+bevacizumab or GC+PL for 6-10cycles; PL or bevacizumab was then continued until disease progression. In this updated analysis, a Cox proportional hazards model was used to compare OS between the 2 treatment arms. RESULTS: At the data cutoff date (July 19, 2013), 353 patients (72.9%) had died. Median follow-up for OS was 58.2months in the experimental arm and 56.4months in the control arm. Consistent with interim analyses, median OS was comparable between arms (GC+bevacizumab: 33.6months; GC+PL: 32.9months; hazard ratio=0.95; log-rank p=0.65), and was consistent across all examined patient subgroups. The frequency and severity of adverse events were consistent with previous analyses; no new safety concerns were identified. CONCLUSIONS: Results from final OS analysis of the phase 3 OCEANS study showed no significant difference in OS for patients treated with GC+bevacizumab compared with GC+PL.
Authors: Timothy J Perren; Ann Marie Swart; Jacobus Pfisterer; Jonathan A Ledermann; Eric Pujade-Lauraine; Gunnar Kristensen; Mark S Carey; Philip Beale; Andrés Cervantes; Christian Kurzeder; Andreas du Bois; Jalid Sehouli; Rainer Kimmig; Anne Stähle; Fiona Collinson; Sharadah Essapen; Charlie Gourley; Alain Lortholary; Frédéric Selle; Mansoor R Mirza; Arto Leminen; Marie Plante; Dan Stark; Wendi Qian; Mahesh K B Parmar; Amit M Oza Journal: N Engl J Med Date: 2011-12-29 Impact factor: 91.245
Authors: Robert A Burger; Mark F Brady; Michael A Bookman; Gini F Fleming; Bradley J Monk; Helen Huang; Robert S Mannel; Howard D Homesley; Jeffrey Fowler; Benjamin E Greer; Matthew Boente; Michael J Birrer; Sharon X Liang Journal: N Engl J Med Date: 2011-12-29 Impact factor: 91.245
Authors: M J Piccart; K Bertelsen; K James; J Cassidy; C Mangioni; E Simonsen; G Stuart; S Kaye; I Vergote; R Blom; R Grimshaw; R J Atkinson; K D Swenerton; C Trope; M Nardi; J Kaern; S Tumolo; P Timmers; J A Roy; F Lhoas; B Lindvall; M Bacon; A Birt; J E Andersen; B Zee; J Paul; B Baron; S Pecorelli Journal: J Natl Cancer Inst Date: 2000-05-03 Impact factor: 13.506
Authors: Lauren A Baldwin; Bin Huang; Rachel W Miller; Thomas Tucker; Scott T Goodrich; Iwona Podzielinski; Christopher P DeSimone; Fred R Ueland; John R van Nagell; Leigh G Seamon Journal: Obstet Gynecol Date: 2012-09 Impact factor: 7.661
Authors: W P McGuire; W J Hoskins; M F Brady; P R Kucera; E E Partridge; K Y Look; D L Clarke-Pearson; M Davidson Journal: N Engl J Med Date: 1996-01-04 Impact factor: 91.245
Authors: U Wagner; C Marth; R Largillier; J Kaern; C Brown; M Heywood; T Bonaventura; I Vergote; M C Piccirillo; R Fossati; V Gebski; E P Lauraine Journal: Br J Cancer Date: 2012-07-26 Impact factor: 7.640
Authors: Haller J Smith; Tyler R McCaw; Angelina I Londono; Ashwini A Katre; Selene Meza-Perez; Eddy S Yang; Andres Forero; Donald J Buchsbaum; Troy D Randall; J Michael Straughn; Lyse A Norian; Rebecca C Arend Journal: Cancer Date: 2018-11-13 Impact factor: 6.860
Authors: Charlotte Gamble; Laura J Havrilesky; Evan R Myers; Junzo P Chino; Scott Hollenbeck; Jennifer K Plichta; P Kelly Marcom; E Shelley Hwang; Noah D Kauff; Rachel A Greenup Journal: Ann Surg Oncol Date: 2017-07-11 Impact factor: 5.344